Navigation Links
HS-7 Document Regarding Research @ M. D. Anderson Orlando
Date:9/3/2009

GREENVILLE, S.C., Sept. 3 /PRNewswire/ -- HS Pharmaceuticals, LLC and its business partner 7 Oaks Pharmaceutical Corporation have engaged in a collaborative research agreement with M. D. Anderson Cancer Center Orlando to study the effects of its proprietary and patented research compound, HS-7, as an effective treatment for pancreatic cancer. The first preclinical study has shown encouraging results and additional studies are now underway.

The research was conducted by Dr. Cheryl Baker, Director and Assistant Professor, Cancer Research Institute of M. D. Anderson Cancer Center Orlando. In a double-blinded study, HS-7 was injected into nude mouse models impregnated with human pancreatic cancer tissue. Reported results indicate that HS-7 demonstrated promising anti-cancer activity. Dr. Baker will continue with the next phase of preclinical studies and M. D. Anderson Cancer Center Orlando will work with HS Pharmaceuticals, LLC and 7 Oaks Pharmaceutical Corporation to progress the HS-7 compound into Phase 1 clinical trials for pancreatic cancer.

The companies have also contracted with Dr. Thomas Wagner (Director, Oncology Research Institute, Greeneville Hospital System) and Dr. Gunter Schwamberger (Professor, University of Salzburg, Austria) to research additional oncology applications for HS-7. Dr. Wagner and Dr. Schwamberger are now conducting animal studies on the compound's effect in melanoma, lymphoma, leukemia, and sarcoma models.


'/>"/>
SOURCE HS Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. University of Redlands Student Cody Unser Documentary Run to Start Today in L.A.
2. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
3. Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
4. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
5. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
8. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. MannKind Addresses Pfizers Announcement Regarding Exubera
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set ... one video to the next without having to set a single keyframe in ... to enhance your video production. , TransDark features dynamic transitions that momentarily splits the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... An April 24th article on ... stunning 180 pounds with the help of a weight loss surgery. The woman, declaring “I ... skin that have been left following her dramatic weight loss. Dr. Feiz & Associates notes ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Beginning in 2017, ... their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that ... the formula in the following ways:, , Removal of the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):